Inspire Medical (DE:2DR)
NYSE:2DR
2DR Stock Chart & Stats
€47.60
€6.05(3.07%)
At close: 4:00 PM EST
€47.60
€6.05(3.07%)
Day’s Range― - ―
52-Week Range€33.60 - €121.90
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
€1.03B
Enterprise Value€1.12B
Total Cash (Recent Filing)€283.83M
Total Debt (Recent Filing)€29.55M
Price to Earnings (P/E)9.0
Beta0.34
Next Earnings
Aug 04, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.53
Shares Outstanding28,813,152
10 Day Avg. Volume0
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.47
Price to Sales (P/S)2.97
P/FCF Ratio34.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€45.47Price Target Upside-4.47% Downside
Rating ConsensusHold
Number of Analyst Covering12
EPS Forecast (FY)0.77
Revenue Forecast (FY)€724.13M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and a large cash position provide durable financial flexibility to absorb reimbursement shocks, fund commercial investments, support inventory strategy, and pursue R&D or opportunistic capital uses without relying on external financing. This reduces solvency risk over the medium term.
High Margins And Cash GenerationSustained, very high gross margins combined with positive operating and free cash flow underpin durable earnings power and internal funding capacity. These margin characteristics support scalability as procedure volume grows and cushion profit performance against near-term revenue volatility.
Clinical Adoption And Product MomentumBroad clinical validation, published outcomes, and a large installed base drive durable referral pathways and physician trust. Continued trial results and commercial uptake of Inspire V create a structural runway for procedure volume expansion as reimbursement barriers ease.
Bears Say
Coding / Reimbursement UncertaintyPersistent coding ambiguity materially impairs access and billing consistency, reducing provider willingness to schedule implants. Because coding frameworks and CPT changes can take years to resolve, this is a structural risk that can depress procedure volumes and revenues through 2027–2028.
Prior-authorization (WISER) HeadwindAI-driven prior authorization programs create durable friction in access if expanded, adding unpredictable volume lags and administrative burden. Extended PA delays directly cut near-term procedures and can erode referral momentum, making revenue recovery slower even after clinical issues are addressed.
Commercial Coverage & Volume VariabilityTerritory consolidation and reduced field coverage while addressing reimbursement issues can lower sales penetration and referral captures. Combined with volatile yearly margins and a revenue guide cut, this suggests commercial execution faces structural challenges that may slow consistent procedure growth.
Inspire Medical Systems News
2DR FAQ
What was Inspire Medical’s price range in the past 12 months?
Inspire Medical lowest stock price was €33.60 and its highest was €121.90 in the past 12 months.
What is Inspire Medical’s market cap?
Inspire Medical’s market cap is €1.03B.
When is Inspire Medical’s upcoming earnings report date?
Inspire Medical’s upcoming earnings report date is Aug 04, 2026 which is in 56 days.
How were Inspire Medical’s earnings last quarter?
Inspire Medical released its earnings results on May 04, 2026. The company reported €0.085 earnings per share for the quarter, beating the consensus estimate of -€0.235 by €0.32.
Is Inspire Medical overvalued?
According to Wall Street analysts Inspire Medical’s price is currently Overvalued.
Does Inspire Medical pay dividends?
Inspire Medical does not currently pay dividends.
What is Inspire Medical’s EPS estimate?
Inspire Medical’s EPS estimate is -0.21.
How many shares outstanding does Inspire Medical have?
Inspire Medical has 28,813,152 shares outstanding.
What happened to Inspire Medical’s price movement after its last earnings report?
Inspire Medical reported an EPS of €0.085 in its last earnings report, beating expectations of -€0.235. Following the earnings report the stock price went down -21.429%.
Which hedge fund is a major shareholder of Inspire Medical?
Currently, no hedge funds are holding shares in DE:2DR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inspire Medical Systems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€45.47 (-4.47% Downside)
€45.47 (-4.47% Downside)
Blogger Sentiment
Bullish
DE:2DR Sentiment 80%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €124.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.68%
12-Months-Change
Fundamentals
Return on Equity
17.98%
Trailing 12-Months
Asset Growth
24.71%
Trailing 12-Months
Company Description
Inspire Medical
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.
2DR Company Deck
2DR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced/Neutral — The company delivered modest revenue growth, margin expansion, stronger operating cash flow, a solid cash position, and meaningful clinical progress, but faces material near-term headwinds from coding and reimbursement uncertainty and the WISER pilot that prompted a significant revenue guide reduction and short-term profitability pressure. Management outlined actions to mitigate the disruption (education, field reimbursement hiring, inventory strategy, targeted investments) and expects improvement later in 2026, while a permanent coding solution (new CPT) is not expected until 2028.View all DE:2DR earnings summaries2DR Revenue Breakdown
97.02% U.S.
2.98% Other
2DR Stock 12 Month Forecast
Average Price Target
€45.47
▼(-4.47% Downside)
Technical Analysis
Integer Holdings
―
LivaNova
―
Irhythm Technologies
―
TransMedics Group
―
PROCEPT BioRobotics
―
Options Prices
Currently, No data available
---